AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 202 min read$MYGN

Myriad to sell prenatal health business to Labcorp (MYGN:NASDAQ)

Myriad Genetics (MYGN) rose over 20% premarket after agreeing to sell its Prenatal Health business to Labcorp (LH) for over $210M in an all-cash deal.

Original reporting
seekingalpha.com
Published Oct 20, 2026, 1:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 1:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$MYGN
Bullish
high confidence
Mentioned
$MYGN · $LH
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$MYGNBullishHigh
01

Why it matters

The deal adds a high‑growth prenatal testing line to Labcorp while providing Myriad shareholders a premium, driving a sharp pre‑market rally for Myriad.

02

Market read

A material M&A announcement with a >$200M cash price and a >20% stock move, offering immediate trading opportunities.

03

What to watch

Regulatory approval timelines for the prenatal test portfolio could delay value realization.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Myriad Genetics, a molecular diagnostics firm, is selling its prenatal health unit to Labcorp in an all‑cash transaction.

Company-level read

Ticker impact

$MYGNBullishHigh confidence
Context

Myriad Genetics announced a cash sale of its Prenatal Health business to Labcorp, triggering a >20% pre‑market price jump.

Expected impact

upward pressure as the market prices in the cash premium and strategic fit.

Evidence & confidence

The deal size is material, the transaction is newly disclosed, and the stock already moved >20% pre‑market.

$LHNeutralMedium confidence
Context

Labcorp agreed to acquire Myriad's Prenatal Health testing unit for over $210M, expanding its diagnostics portfolio.

Expected impact

modest upside as investors price in the strategic acquisition.

Evidence & confidence

The acquisition is sizable but the immediate price reaction is muted compared with Myriad's share jump.

Market effects

Sector

Strengthens the diagnostics and prenatal testing segment, potentially prompting competitive moves.

Regional

U.S. healthcare sector may see modest uplift as a large cash deal signals confidence.

Global

Limited to U.S. biotech and diagnostics markets.

Counterpoint

What could challenge this read

If the integration costs exceed expectations, Labcorp's stock could face pressure despite the strategic fit.

Key entities

  • company
    Myriad Genetics

    Seller of the prenatal health business.

  • company
    Labcorp

    Buyer acquiring the prenatal health unit.

Read at source← All news

StoryMyriad Genetics to sell its Prenatal Health unit to Labcorp for $210 million in cash

Also covered by

5 outlets

Related articles

OCT 20
$MYGNHighAI 9/10

Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

investorideas.com2 min
OCT 20
$QGENMed

Qiagen Deal Chatter Lifted US Healthcare Stocks

EQT offered $50+ per share for Qiagen, raising its stock 5.8%. Labcorp agreed to buy Myriad Genetics' prenatal testing unit for $210M, boosting Myriad 36% and Labcorp 1%. GeneDx gained on sequencing plans. Investors focus on deal probabilities and sector-wide M&A expectations.

finimize.com2 min
OCT 20
$MYGNMed

TD Cowen holds Myriad Genetics stock rating on Labcorp sale

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics stock surges on $210M prenatal unit sale

Myriad Genetics (MYGN) shares rose 36% after announcing a $210M sale of its prenatal testing unit to Labcorp (LH). The deal includes tests generating $160M in annual revenue. Myriad expects the sale to boost growth and profitability, while Labcorp anticipates added revenue and slight earnings accretion. The transaction is expected to close by early 2027, pending regulatory approval.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) shares rose 22.2% premarket after agreeing to sell its Prenatal Health business to Labcorp for $210M in cash plus inventory. The deal, expected to close by early 2027, includes a $10.5M reverse termination fee. The prenatal division had seen a 16% YoY revenue decline in Q2. CEO Sam Raha stated the divestiture will improve overall revenue growth and profitability.

financialcontent.com2 min
OCT 20
$MYGNHighAI 8/10

Myriad Genetics (MYGN) Shares Surge 20% Premarket on Prenatal He

Myriad Genetics (MYGN) shares rose 20% premarket after announcing the sale of its Prenatal Health division to Labcorp for $210M. Labcorp expects $160M in first-year revenue from the acquisition. MYGN's P/S ratio is 0.49, below historical and industry averages, reflecting market skepticism about growth. The company's GF Score is 47, indicating moderate financial health with weak growth and profitability.

gurufocus.com2 min